aspergillosis pipeline insight

DelveInsight’s, “Aspergillosis- Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Aspergillosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Aspergillosis: Understanding

Aspergillosis: Overview

Aspergillosis refers to a group of diseases caused by the Aspergillus species, a common type of mold found in the environment. This fungus is typically harmless to individuals with healthy immune systems, but it can cause a range of conditions, especially in people with weakened immunity or preexisting lung conditions. The most common species responsible is Aspergillus fumigatus, although other species like A. flavus and A. niger can also be pathogenic.

 

There are several forms of aspergillosis, with varying degrees of severity. Allergic bronchopulmonary aspergillosis (ABPA) occurs in people with asthma or cystic fibrosis and results in an allergic reaction that leads to inflammation in the lungs. Chronic pulmonary aspergillosis (CPA) can develop in patients with underlying lung diseases like tuberculosis, and may cause long-term lung damage, weight loss, and fatigue. The most severe form is invasive aspergillosis, which occurs when the fungus spreads from the lungs to other organs. This form is life-threatening and typically affects people undergoing chemotherapy, organ transplantation, or those with severely compromised immune systems.

 

Diagnosis of aspergillosis depends on the form and severity of the disease. It typically involves imaging tests like chest X-rays or CT scans, as well as laboratory testing of respiratory samples or blood for fungal markers. In some cases, a biopsy may be needed to confirm the diagnosis. Due to its nonspecific symptoms such as cough, fever, and shortness of breath, aspergillosis can be challenging to distinguish from other respiratory conditions, especially in immunocompromised patients.

 

Treatment for aspergillosis varies by type. Antifungal medications like voriconazole or isavuconazole are commonly used for invasive forms, while corticosteroids and antifungals are often combined for ABPA. Surgical intervention may be necessary in some cases, particularly when fungal balls (aspergillomas) are present in the lungs. Managing underlying conditions and reducing immunosuppression when possible are also critical components of treatment.

 

Preventive measures are especially important for high-risk individuals. These include avoiding environments with high levels of mold, such as construction sites or compost areas, and using HEPA filters in indoor spaces. For immunocompromised patients, antifungal prophylaxis may be considered. With rising awareness and improved diagnostic methods, early detection and management of aspergillosis can significantly improve patient outcomes.

 

"Aspergillosis- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Aspergillosis pipeline landscape is provided which includes the disease overview and Aspergillosis treatment guidelines. The assessment part of the report embraces, in depth Aspergillosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Aspergillosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Aspergillosis R&D. The therapies under development are focused on novel approaches to treat/improve Aspergillosis. 

 

Aspergillosis Emerging Drugs Chapters

This segment of the Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Aspergillosis Emerging Drugs

• Opelconazole: Pulmocide

Opelconazole is a new chemical entity designed to be delivered as an inhaled antifungal agent specifically intended for activity in the lungs, where most Aspergillus disease occurs. Opelconazole has been shown to inhibit the growth of Aspergillus fumigatus clinical isolates and other pathogenic Aspergillus species, such as Aspergillus terreus, Aspergillus flavus, and Aspergillus carbonarius in vitro.14 The anti-Aspergillus fumigatus effect has also been demonstrated in vitro and in non-clinical in vivo studies, with encouraging results having also been observed in patients participating in a limited “Specials” program (similar to a compassionate use program) ongoing in the United Kingdom. Currently, the drug is in the Phase III stage of its development for the treatment of Aspergillosis.

 

• PUR1900: Cipla/Pulmatrix

PUR1900, also known as Pulmazole, is an inhaled dry powder formulation of the antifungal drug itraconazole, developed by Pulmatrix using its proprietary iSPERSE™ technology. This formulation aims to treat allergic bronchopulmonary aspergillosis (ABPA) in asthma patients by delivering the medication directly to the lungs, thereby enhancing local efficacy and minimizing systemic side effects associated with oral itraconazole.

 

Clinical studies have demonstrated that PUR1900 achieves significantly higher lung concentrations and substantially lower plasma exposure compared to oral itraconazole. This pharmacokinetic profile suggests a potential for improved safety and efficacy in treating ABPA. The most common adverse event reported was a mild, transient cough immediately after inhalation. The drug is in Phase II stage of its development for the treatment of Aspergillosis. 

Further product details are provided in the report……..

 

Aspergillosis: Therapeutic Assessment

This segment of the report provides insights about the different Aspergillosis drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Aspergillosis

There are approx. 10+ key companies which are developing the therapies for Aspergillosis. The companies which have their Aspergillosis drug candidates in the most advanced stage, i.e. Phase III include, Pulmocide.

 

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Aspergillosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Aspergillosis: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Aspergillosis therapeutic drugs key players involved in developing key drugs. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aspergillosis drugs.

 

Aspergillosis Report Insights

• Aspergillosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Aspergillosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Aspergillosis drugs?
• How many Aspergillosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aspergillosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aspergillosis therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Aspergillosis and their status?
• What are the key designations that have been granted to the emerging drugs?